Drug Profile
Epoetin kappa - JCR Pharmaceuticals
Alternative Names: Epoetin alfa biosimilar - JCR Pharmaceuticals/Kissei Pharmaceuticals; Epoetin alfa biosimilar 1; Epoetin Alfa BS Injection [JCR]; Epoetin Alpha BS Inj. JCR; JR-013Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Developer JCR Pharmaceuticals; Kissei Pharmaceutical
- Class Antianaemics; Haematopoietic cell growth factors; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 27 May 2010 Launched for Anaemia (in neonates) in Japan (SC) - first global launch
- 27 May 2010 Launched for Anaemia (renal anaemia in patients undergoing dialysis) in Japan (IV) - first global launch
- 20 Jan 2010 Registered for Anaemia (in neonates) in Japan (SC)